FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1646997108> ?p ?o ?g. }

• W1646997108 abstract "In myasthenia gravis, antibody-mediated blockade of acetylcholine receptors at the neuromuscular junction abolishes the naturally occurring 'safety factor' of synaptic transmission. Acetylcholinesterase inhibitors provide temporary symptomatic treatment of muscle weakness but there is controversy about their long-term efficacy, dosage and side effects. This is the second update of a review published in The Cochrane Library Issue 2, 2011.To evaluate the efficacy of acetylcholinesterase inhibitors in all forms of myasthenia gravis.On 8 July 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE and EMBASE for randomised controlled trials and quasi-randomised controlled trials regarding usage of acetylcholinesterase inhibitors in myasthenia gravis. Two authors scanned the articles for any study eligible for inclusion. We also contacted the authors and known experts in the field to identify additional published or unpublished data and searched clinical trials registries for ongoing trials.The types of studies were randomised or quasi-randomised trials. Participants were myasthenia gravis patients diagnosed by an internationally accepted definition. The intervention was treatment with any form of acetylcholinesterase inhibitor. Types of outcome measures Primary outcome measureImprovement in the presenting symptoms within one to 14 days of the start of treatment. Secondary outcome measures(1) Improvement in the presenting symptoms more than 14 days after the start of treatment.(2) Change in impairment measured by a recognised and preferably validated scale, such as the quantitative myasthenia gravis score, within one to 14 days and more than 14 days after the start of treatment.(3) Myasthenia Gravis Association of America post-intervention status more than 14 days after start of treatment.(4) Adverse events including muscarinic side effects.One author (MMM) extracted the data, which were checked by a second author. We contacted study authors for extra information and collected data on adverse effects from the trials.We did not find any large randomised or quasi-randomised trials of acetylcholinesterase inhibitors in generalised myasthenia gravis either for the first version of this review or this update. One cross-over randomised trial using intranasal neostigmine in a total of 10 participants was only available as an abstract. It included three participants with ocular myasthenia gravis and seven with generalised myasthenia gravis. Symptoms of myasthenia gravis (measured as improvement in at least one muscle function) improved in nine of the 10 participants after the two-week neostigmine treatment phase. No participant improved after the placebo phase. Lack of detail in the report meant that the risk of bias was unclear. Adverse events were minor.Except for one small and inconclusive trial of intranasal neostigmine, no other randomised controlled trials have been conducted on the use of acetylcholinesterase inhibitors in myasthenia gravis. The response to acetylcholinesterase inhibitors in observational studies is so clear that a randomised controlled trial depriving participants in a placebo arm of treatment would be difficult to justify." @default.
• W1646997108 created "2016-06-24" @default.
• W1646997108 creator A5019194539 @default.
• W1646997108 creator A5032536875 @default.
• W1646997108 creator A5049283145 @default.
• W1646997108 date "2014-10-13" @default.
• W1646997108 modified "2023-10-02" @default.
• W1646997108 title "Acetylcholinesterase inhibitor treatment for myasthenia gravis" @default.
• W1646997108 cites W1522542401 @default.
• W1646997108 cites W1585785281 @default.
• W1646997108 cites W1598602811 @default.
• W1646997108 cites W1646997108 @default.
• W1646997108 cites W1647526924 @default.
• W1646997108 cites W1885488829 @default.
• W1646997108 cites W1900349041 @default.
• W1646997108 cites W1925036085 @default.
• W1646997108 cites W1975633090 @default.
• W1646997108 cites W1975997968 @default.
• W1646997108 cites W1983404333 @default.
• W1646997108 cites W1984685847 @default.
• W1646997108 cites W1990217869 @default.
• W1646997108 cites W2008765276 @default.
• W1646997108 cites W2008971303 @default.
• W1646997108 cites W2009061035 @default.
• W1646997108 cites W2023200671 @default.
• W1646997108 cites W2028885674 @default.
• W1646997108 cites W2038591428 @default.
• W1646997108 cites W2053086806 @default.
• W1646997108 cites W2054103465 @default.
• W1646997108 cites W2059718454 @default.
• W1646997108 cites W2076440072 @default.
• W1646997108 cites W2076655703 @default.
• W1646997108 cites W2077383563 @default.
• W1646997108 cites W2109351747 @default.
• W1646997108 cites W2116403969 @default.
• W1646997108 cites W2121517394 @default.
• W1646997108 cites W2121758832 @default.
• W1646997108 cites W2142966697 @default.
• W1646997108 cites W2146831407 @default.
• W1646997108 cites W2151141868 @default.
• W1646997108 cites W2151320612 @default.
• W1646997108 cites W2154180887 @default.
• W1646997108 cites W2168644179 @default.
• W1646997108 cites W2320125573 @default.
• W1646997108 cites W2350080436 @default.
• W1646997108 cites W2399904259 @default.
• W1646997108 cites W2407014693 @default.
• W1646997108 cites W2764694754 @default.
• W1646997108 cites W4236359430 @default.
• W1646997108 cites W4246094258 @default.
• W1646997108 cites W4248406156 @default.
• W1646997108 cites W4249498002 @default.
• W1646997108 cites W4252493259 @default.
• W1646997108 cites W4255668698 @default.
• W1646997108 doi "https://doi.org/10.1002/14651858.cd006986.pub3" @default.
• W1646997108 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7390275" @default.
• W1646997108 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25310725" @default.
• W1646997108 hasPublicationYear "2014" @default.
• W1646997108 type Work @default.
• W1646997108 sameAs 1646997108 @default.
• W1646997108 citedByCount "49" @default.
• W1646997108 countsByYear W16469971082012 @default.
• W1646997108 countsByYear W16469971082013 @default.
• W1646997108 countsByYear W16469971082014 @default.
• W1646997108 countsByYear W16469971082015 @default.
• W1646997108 countsByYear W16469971082016 @default.
• W1646997108 countsByYear W16469971082017 @default.
• W1646997108 countsByYear W16469971082018 @default.
• W1646997108 countsByYear W16469971082019 @default.
• W1646997108 countsByYear W16469971082020 @default.
• W1646997108 countsByYear W16469971082021 @default.
• W1646997108 countsByYear W16469971082022 @default.
• W1646997108 countsByYear W16469971082023 @default.
• W1646997108 crossrefType "journal-article" @default.
• W1646997108 hasAuthorship W1646997108A5019194539 @default.
• W1646997108 hasAuthorship W1646997108A5032536875 @default.
• W1646997108 hasAuthorship W1646997108A5049283145 @default.
• W1646997108 hasBestOaLocation W16469971082 @default.
• W1646997108 hasConcept C126322002 @default.
• W1646997108 hasConcept C141071460 @default.
• W1646997108 hasConcept C168563851 @default.
• W1646997108 hasConcept C181199279 @default.
• W1646997108 hasConcept C185592680 @default.
• W1646997108 hasConcept C197934379 @default.
• W1646997108 hasConcept C2776356578 @default.
• W1646997108 hasConcept C2776418732 @default.
• W1646997108 hasConcept C2776478404 @default.
• W1646997108 hasConcept C2778105408 @default.
• W1646997108 hasConcept C2778816929 @default.
• W1646997108 hasConcept C2779134260 @default.
• W1646997108 hasConcept C2780247198 @default.
• W1646997108 hasConcept C3020341438 @default.
• W1646997108 hasConcept C535046627 @default.
• W1646997108 hasConcept C55493867 @default.
• W1646997108 hasConcept C71924100 @default.
• W1646997108 hasConceptScore W1646997108C126322002 @default.
• W1646997108 hasConceptScore W1646997108C141071460 @default.
• W1646997108 hasConceptScore W1646997108C168563851 @default.
• W1646997108 hasConceptScore W1646997108C181199279 @default.
• W1646997108 hasConceptScore W1646997108C185592680 @default.

• next